These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 24953848

  • 1. Incidence of malignant neoplasia after heart transplantation--a comparison between cyclosporine a and tacrolimus.
    Fuchs U, Klein S, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Ann Transplant; 2014 Jun 23; 19():300-4. PubMed ID: 24953848
    [Abstract] [Full Text] [Related]

  • 2. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U, Zittermann A, Ensminger SM, Schulz U, Gummert JF.
    Transpl Immunol; 2014 Aug 23; 31(2):87-91. PubMed ID: 24932812
    [Abstract] [Full Text] [Related]

  • 3. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results.
    Bolin P, Shihab FS, Mulloy L, Henning AK, Gao J, Bartucci M, Holman J, First MR, OPTIMA Study Group.
    Transplantation; 2008 Jul 15; 86(1):88-95. PubMed ID: 18622283
    [Abstract] [Full Text] [Related]

  • 4. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
    Nankivell BJ, PʼNg CH, OʼConnell PJ, Chapman JR.
    Transplantation; 2016 Aug 15; 100(8):1723-31. PubMed ID: 27306529
    [Abstract] [Full Text] [Related]

  • 5. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine.
    Castel MA, Farrero M, Vallejos I, Cardona M, Regueiro A, Pérez-Villa F.
    Transplant Proc; 2011 Aug 15; 43(6):2244-6. PubMed ID: 21839245
    [Abstract] [Full Text] [Related]

  • 6. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS, Li J, Chen XT, Zhang HX, Fu Q, Wang HY, Xiong YY, Liu S, Liu XM, Li JL, Huang M, Wang CX.
    Int J Clin Pract Suppl; 2015 May 15; (183):43-52. PubMed ID: 26177348
    [Abstract] [Full Text] [Related]

  • 7. Impact of type of calcineurin inhibitor on post-transplant tuberculosis: Single-center study from India.
    Agarwal SK, Bhowmik D, Mahajan S, Bagchi S.
    Transpl Infect Dis; 2017 Feb 15; 19(1):. PubMed ID: 27775825
    [Abstract] [Full Text] [Related]

  • 8. Calcineurin inhibitors and Clostridium difficile infection in adult lung transplant recipients: the effect of cyclosporine versus tacrolimus.
    Lee JT, Whitson BA, Kelly RF, D'Cunha J, Dunitz JM, Hertz MI, Shumway SJ.
    J Surg Res; 2013 Sep 15; 184(1):599-604. PubMed ID: 23566442
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May 15; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D, Miquel R, Porrini E, Fernández A, González-Posada JM, Hortal L, Checa MD, Rodríguez A, García JJ, Rufino M, Torres A.
    Transplantation; 2007 Sep 27; 84(6):706-14. PubMed ID: 17893603
    [Abstract] [Full Text] [Related]

  • 11. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
    Charpentier B, Rostaing L, Berthoux F, Lang P, Civati G, Touraine JL, Squifflet JP, Vialtel P, Abramowicz D, Mourad G, Wolf P, Cassuto E, Moulin B, Rifle G, Pruna A, Merville P, Mignon F, Legendre C, Le Pogamp P, Lebranchu Y, Toupance O, Hurault De Ligny B, Touchard G, Olmer M, Purgus R, Pouteil-Noble C, Glotz D, Bourbigot B, Leski M, Wauters JP, Kessler M.
    Transplantation; 2003 Mar 27; 75(6):844-51. PubMed ID: 12660513
    [Abstract] [Full Text] [Related]

  • 12. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain V, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K.
    Liver Transpl; 2003 Jun 27; 9(6):587-95. PubMed ID: 12783400
    [Abstract] [Full Text] [Related]

  • 13. Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation.
    Helmschrott M, Rivinius R, Ruhparwar A, Schmack B, Erbel C, Gleissner CA, Akhavanpoor M, Frankenstein L, Ehlermann P, Bruckner T, Katus HA, Doesch AO.
    Drug Des Devel Ther; 2015 Jun 27; 9():1217-24. PubMed ID: 25759566
    [Abstract] [Full Text] [Related]

  • 14. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O, Mayer DA, Boudjema K, Salizzoni M, Gridelli B, Filipponi F, Trunecka P, Krawczyk M, Clavien PA, Ducerf C, Margarit C, Margreiter R, Pallardo JM, Hoeckerstedt K, Pageaux GP.
    Liver Transpl; 2005 Jan 27; 11(1):61-7. PubMed ID: 15690537
    [Abstract] [Full Text] [Related]

  • 15. Risk Factors Affecting Graft and Patient Survivals After Transplantation From Deceased Donors in a Developing Country: A Single-Center Experience.
    Ayar Y, Ersoy A, Ocakoglu G, Yildiz A, Oruc A, Soyak H, Calapkulu M, Sahin AB, Topal NB, Okeer E, Coskun B, Kaygisiz O, Kordan Y, Vuruskan H.
    Transplant Proc; 2017 Mar 27; 49(2):270-277. PubMed ID: 28219583
    [Abstract] [Full Text] [Related]

  • 16. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
    de Sandes-Freitas TV, Felipe CR, Campos ÉF, de Lima MG, Soares MF, de Franco MF, Aguiar WF, Tedesco-Silva H, Medina-Pestana JO.
    Transplantation; 2015 Nov 27; 99(11):2372-81. PubMed ID: 25929604
    [Abstract] [Full Text] [Related]

  • 17. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S, Kling N, Bechstein WO, Blumhardt G, Lohmann R, Lobeck H, Neuhaus P.
    Clin Transplant; 1995 Oct 27; 9(5):406-14. PubMed ID: 8541635
    [Abstract] [Full Text] [Related]

  • 18. Role of dendritic cells in the context of acute cellular rejection: comparison between tacrolimus- or cyclosporine A-treated heart transplanted recipients.
    John K, Dieterlen MT, Tarnok A, Garbade J, Bittner HB, Mohr FW, Barten MJ.
    Cytometry B Clin Cytom; 2014 Sep 27; 86(5):362-7. PubMed ID: 24668729
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan.
    Wang CH, Ko WJ, Chou NK, Wang SS.
    Transplant Proc; 2004 Oct 27; 36(8):2384-5. PubMed ID: 15561256
    [Abstract] [Full Text] [Related]

  • 20. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.